Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
116. |
ECCT/19/02/01 | DANCE Study An Open-Label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-Drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-Infected Adolescents, ≥12 To <18 Years of Age who Weigh at Least 40 Kg. |
Principal Investigator(s) 1. Fredrick Odhiambo Otieno 2. Isaac Tsikhutsu Site(s) in Kenya 1. Nyanza Reproductive Health Society (Kisumu county) 2. Kenya Medical Research Institute (Kisumu county) 3. Kenya Medical Research Institute, Walter Reed Project (Kericho county) |
View |
117. |
ECCT/13/03/02 | An open-label, pilot demonstration and evaluation project of antiretroviral-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples An open-label, pilot demonstration and evaluation project of antiretroviral-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples The Partners PrEP Study Demonstration Project |
Principal Investigator(s) 1. DR.ELIZABETH ANNE BUKUSI ELIZABETH ANNE BUKUSI Site(s) in Kenya 1. THIKA (Nairobi City county) |
View |
118. |
ECCT/12/08/01 | Partners Demonstration Project An open-label, pilot demonstration and evaluation project of antiretrovira-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples. |
Principal Investigator(s) 1. Dr. Nelly Rwamba Mugo Site(s) in Kenya 1. Partners in Prevention, Thika Site (Kiambu county) 2. Partners in Prevention, Kisumu Site (Kisumu county) |
View |
119. |
ECCT/19/04/03 | Phase III pediatric study with the L-PZQ ODTs An Open-label, Phase 3 efficacy and safety study of L-praziquantel orodispersible tablets (L-PZQ ODT) in Schistosoma-infected children 3 months to 6 years of age, including a 2:1 randomized, controlled cohort of Schistosoma mansoni-infected children 4 to 6 years of age treated with L-PZQ ODT or commercial PZQ (Biltricide®) |
Principal Investigator(s) 1. Maurice Reuben Odiere Site(s) in Kenya KEMRI-Centre for Global Health Research (CGHR) |
View |
120. |
ECCT/25/01/01 | FLORAL An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study. |
Principal Investigator(s) 1. Bernhard Ogutu Site(s) in Kenya 1. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county) 2. Gertrude’s Children’s Hospital (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) 5. KEMRI WALTER REED KERICHO (Kericho county) 6. KEMRI Kondele Children\'s Hospital (Kisumu county) 7. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) |
View |